Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant

Nucleic Acid Therapeutics

Volumn 26, Issue 1, 2016, Pages 1-9

  Soule, Erin E ^a   Bompiani, Kristin M ^a,b   Woodruff, Rebecca S ^a,c,d   Sullenger, Bruce A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Bloodworks Northwest Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDOTE; APTAMER; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; PROTEINASE; PROTHROMBIN; RNA; RNA BA1 ANTIDOTE; RNA BA2 ANTIDOTE; RNA BA3 ANTIDOTE; RNA BA4 ANTIDOTE; THROMBIN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR; SERINE PROTEINASE;

ANTICOAGULATION; ARTICLE; BINDING AFFINITY; DEPHOSPHORYLATION; ISOTOPE LABELING; PRIORITY JOURNAL; RNA SEQUENCE; CHEMISTRY; CONFORMATION; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ANTICOAGULANTS; ANTIDOTES; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BLOOD COAGULATION FACTORS; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; SERINE PROTEASES;

EID: 84957700826     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2015.0565     Document Type: Article

References (33)

1. Davie EW and OD Ratnoff. (1964). Waterfall sequence for intrinsic blood clotting. Science 145:1310-1312.
2. Macfarlane RG. (1964). An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202:498-499.
3. Hoffman M and DM Monroe, III. (2001). A cell-based model of hemostasis. Thromb Haemost 85:958-965.
4. Bussey H and JL Francis. (2004). Heparin overview and issues. Pharmacotherapy 24(8 Pt 2):103s-107s.
5. Hirsh J, TE Warkentin, R Raschke, C Granger, EM Ohman and JE Dalen. (1998). Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114(5 Suppl):489s-510s.
6. Ellington AD and JW Szostak. (1990). In vitro selection of RNAmolecules that bind specific ligands.Nature 346:818-822.
7. Tuerk C and L Gold. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
8. Rusconi CP, E Scardino, J Layzer, GA Pitoc, TL Ortel, D Monroe and BA Sullenger. (2002). RNAaptamers as reversible antagonists of coagulation factor IXa. Nature 419:90-94.
9. Buddai SK, JM Layzer, G Lu, CP Rusconi, BA Sullenger, DM Monroe and S Krishnaswamy. (2010). An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. J Biol Chem 285:5212-5223.
10. Bompiani KM, DM Monroe, FC Church and BA Sullenger. (2012). A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. J Thromb Haemost 10:870-880.
11. Layzer JM and BA Sullenger. (2007). Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides 17:1-11.
12. Sullenger B, R Woodruff and DM Monroe. (2012). Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction. JBiolChem 287:12779-12786.
13. Oney S, RT Lam, KM Bompiani, CM Blake, G Quick, JD Heidel, JY Liu, BC Mack, ME Davis, KW Leong and BA Sullenger. (2009). Development of universal antidotes to control aptamer activity. Nat Med 15:1224-1228.
14. Povsic TJ, JP Vavalle, JH Alexander, LH Aberle, SL Zelenkofske, RC Becker, CE Buller, MG Cohen, JH Cornel, et al. (2014). Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. EuroIntervention 10:431-438.
15. Cohen MG, DA Purdy, JS Rossi, LR Grinfeld, SK Myles, LH Aberle, AB Greenbaum, E Fry, MY Chan, et al. (2010). First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 122:614-622.
16. Povsic TJ, WA Wargin, JH Alexander, J Krasnow, M Krolick, MG Cohen, R Mehran, CE Buller, C Bode, et al. (2011). Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. Eur Heart J 32:2412-2419.
17. Povsic TJ, JP Vavalle, LH Aberle, JD Kasprzak, MG Cohen, RMehran, C Bode, CE Buller, GMontalescot, et al. (2013).A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J 34:2481-2489.
18. Bompiani KM, JL Lohrmann, GA Pitoc, JW Frederiksen, GB Mackensen and BA Sullenger. (2014). Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation. Chem Biol 21:935-944.
19. Dyke CK, SR Steinhubl, NS Kleiman, RO Cannon, LG Aberle, M Lin, SK Myles, C Melloni, RA Harrington, et al. (2006). First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114:2490-2497.
20. Musumeci D and D Montesarchio. (2012). Polyvalent nucleic acid aptamers and modulation of their activity: a focus on the thrombin binding aptamer. Pharmacol Ther 136:202-215.
21. Dollins CM, S Nair, D Boczkowski, J Lee, JM Layzer, E Gilboa and BA Sullenger. (2008). Assembling OX40 aptamers on a molecular scaffold to create a receptoractivating aptamer. Chem Biol 15:675-682.
22. McNamara JO, DKolonias, F Pastor, RS Mittler, L Chen, PH Giangrande, B Sullenger and E Gilboa. (2008). Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest 118:376-386.
23. Gilboa E, J McNamara, II and F Pastor. (2013). Use of oligonucleotide aptamer ligands to modulate the function of immune receptors. Clin Cancer Res 19:1054-1062.
24. Kim Y, Z Cao and W Tan. (2008). Molecular assembly for high-performance bivalent nucleic acid inhibitor. Proc Natl Acad Sci U S A 105:5664-5669.
25. Kim Y, DM Dennis, T Morey, L Yang and W Tan. (2010). Engineering dendritic aptamer assemblies as superior inhibitors of protein function. Chem Asian J 5:56-59.
26. Nimjee SM, S Oney, Z Volovyk, KM Bompiani, SB Long, M Hoffman and BA Sullenger. (2009). Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. RNA 15:2105-2111.
27. Rangnekar A, AM Zhang, SS Li, KM Bompiani, MN Hansen, KV Gothelf, BA Sullenger and TH LaBean. (2012). Increased anticoagulant activity of thrombinbinding DNA aptamers by nanoscale organization on DNA nanostructures. Nanomedicine 8:673-681.
28. Subbaiah PV, SS Bajwa, CMSmith and DJ Hanahan. (1976). Interactions of the components of the prothrombinase complex. Biochim Biophys Acta 444:131-146.
29. Mann KG, ME Nesheim, PB Tracy, LS Hibbard and JW Bloom. (1982). Assembly of the prothrombinase complex. Biophys J 37:106-107.
30. White R, C Rusconi, E Scardino, A Wolberg, J Lawson, M Hoffman and B Sullenger. (2001). Generation of species cross-reactive aptamers using "Toggle" SELEX. Mol Ther 4:567-573.
31. Laszlo GS, CJ Gudgeon, KH Harrington and RB Walter. (2015). T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. Blood Cancer J 5:e340.
32. Kotula JW, J Sun, M Li, ED Pratico, MP Fereshteh, DP Ahrens, BA Sullenger and JJ Kovacs. (2014). Targeted disruption of beta-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth. PLoS One 9:e93441.
33. Schrand B, A Berezhnoy, R Brenneman, A Williams, A Levay and E Gilboa. (2015). Reducing toxicity of 4-1BB costimulation: targeting 4-1BB ligands to the tumor stroma with bi-specific aptamer conjugates. Oncoimmunology 4:e970918.